In various cancers, including cutaneous melanoma, increased activity of the YAP/TAZ pathway has been related to worse survival,29,30 and inhibition of YAP/TAZ has been suggested as a potential new therapy.27 The gene discussed is YAP1; the disease is cutaneous melanoma.